<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085852</url>
  </required_header>
  <id_info>
    <org_study_id>C04-001</org_study_id>
    <secondary_id>IRB Protocol # 2003-P-002171</secondary_id>
    <nct_id>NCT00085852</nct_id>
  </id_info>
  <brief_title>US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation</brief_title>
  <official_title>Phase 1 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Heterogeneous Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeris Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Aeris Bronchoscopic Lung Volume&#xD;
      Reduction (BLVR) System is safe in patients with advanced emphysema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with emphysema currently have limited treatment choices. Many patients are treated&#xD;
      with steroids and inhaled medications, which often provide little or no benefit. Recently,&#xD;
      lung volume reduction surgery has become an accepted therapy for emphysema. Lung volume&#xD;
      reduction surgery involves the removal of a diseased portion of the lung, which enables the&#xD;
      remaining, healthier portions of the lung to function better. This procedure, although&#xD;
      effective, is complicated and risky.&#xD;
&#xD;
      Aeris Therapeutics has developed the Aeris Bronchoscopic Lung Volume Reduction System for&#xD;
      treatment of patients with advanced emphysema. The Aeris BLVR System is designed to reduce&#xD;
      lung volume without surgery. Patients are treated under anesthesia using a bronchoscope to&#xD;
      direct treatment to the most damaged areas of the lung. The treatment is expected to reduce&#xD;
      lung volume by shrinking the diseased areas of the lung. The purpose of the current study is&#xD;
      to find out whether the Aeris BLVR System is safe in patients with advanced emphysema. The&#xD;
      risks associated with the treatment are expected to be similar to those associated with&#xD;
      general anesthesia and bronchoscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAEs - Safety</measure>
    <time_frame>1 year post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFTs</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with BLVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BLVR</intervention_name>
    <description>10 mL Hydrogel</description>
    <arm_group_label>Single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced emphysema&#xD;
&#xD;
          -  Limited exercise capacity and persistent symptoms despite medical therapy&#xD;
&#xD;
          -  Age between 18 and 75&#xD;
&#xD;
          -  No significant heart, kidney or liver disease&#xD;
&#xD;
          -  Willingness and ability to tolerate bronchoscopy&#xD;
&#xD;
          -  No prior Lung Volume Reduction Surgery or Lung Transplantation&#xD;
&#xD;
          -  Screening test results indicating that the procedure is appropriate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John J. Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas St Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ingenito EP, Berger RL, Henderson AC, Reilly JJ, Tsai L, Hoffman A. Bronchoscopic lung volume reduction using tissue engineering principles. Am J Respir Crit Care Med. 2003 Mar 1;167(5):771-8. Epub 2002 Oct 11.</citation>
    <PMID>12406835</PMID>
  </reference>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>June 15, 2004</study_first_submitted>
  <study_first_submitted_qc>June 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2004</study_first_posted>
  <last_update_submitted>February 27, 2008</last_update_submitted>
  <last_update_submitted_qc>February 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Edward P Ingenito, MD, PhD, Medical Director &amp; CSO</name_title>
    <organization>Aeris Therapeutics Inc</organization>
  </responsible_party>
  <keyword>emphysema</keyword>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>lung volume reduction</keyword>
  <keyword>bronchoscopic</keyword>
  <keyword>bronchoscopy</keyword>
  <keyword>bronchoscope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

